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Gene therapyTargeting the HIV entry and assembly pathways holds promise for development of novel anti-HIV gene
therapy vectors. We characterized discrete dominant negative (DN) Gag and Envelope mutants for their anti-
HIV-1 activity. We show here that capsid mutants (Q155N and Y164A) are more potent inhibitors of WT HIV
than the matrix mutant 1GA. Both the Envelope mutants tested, V513E and R515A, were equally effective and
a combination of Gag and Envelope DN genes signiﬁcantly enhanced potency. Interestingly, the DN mutants
acted at multiple steps in the virus life cycle rather than solely disrupting virus release or infection. Inhibition
mediated by R515A could be partially attributed to the Envelope cytoplasmic tail, as deletion of R515A tail
partially abrogated its DN effect. Finally, the Y164A/R515A double mutant expressed in a lentiviral vector was
effective at inhibiting HIV replication in CD34+ hematopoietic stem cell-derived macrophages, demonstrat-
ing the therapeutic potential of our approach.nfectious Disease, Department
Sciences Center, 5001 El Paso
1271.
premlata.shankar@ttuhsc.edu
Inc.Published by Elsevier Inc.Introduction
The rapidly mutating nature of HIV and the adverse effects
associated with routine drug therapy suggests the need for develop-
ment of alternative therapeutic interventions. One of the obvious
alternatives to chemotherapy is gene therapy. Recent advances in
genetic manipulation of CD34+ stem cells, along with the develop-
ment of lentiviral vectors capable of delivering desired genes to non-
dividing cells,havemade HIV-based gene therapy a realistic possibility
(Liu and Berkhout, 2009; Rossi et al., 2007a). Moreover, there is
always a need for novel anti-HIV drugs with unique mechanisms of
action that can be harnessed as salvage therapy in case of intolerance
or resistance to antiretroviral drugs.
One of the most commonly studied conventional gene therapy
approach for controlling HIV infection is the use of shRNAs targeting
viral or host genes (Liu and Berkhout, 2009; Nazari and Joshi, 2008;
Rossi et al., 2007a; Unwalla et al., 2004b). Another attractive alternative
gene therapy approach is to utilize dominant negative (DN) HIV
proteins to target the HIV life cycle which is exempliﬁed by the successof DN rev (RevM10) in inhibiting HIV replication in vitro (Bahner et al.,
2007;Woffendin et al., 1996). However, both shRNA-mediated therapy
and use of DN Rev comes with the caveat that escape mutants usually
arise (Legiewicz et al., 2008). Hence, a combinatorial approach using
both shRNA and DN host or viral genes is critical to target multiple viral
orhostproteins inorder to limit theemergenceof resistantmutants. Just
like long-term shRNA therapy is accompanied by the problem of cell
toxicity due to competition with the host micro-RNA processing
machinery (Liu and Berkhout, 2009; Rossi et al., 2007a), the constitutive
expression of DN HIV proteins could be detrimental to cells due to
toxicity or immune recognition and cytotoxic T cell-mediated elimina-
tion. Moreover, gene therapy itself is associated with the drawbacks
of 1) low transduction efﬁciency of CD34+2) elimination of transduced
cells in vivo over a period of time, 3) potential of emergence of virus
resistance,and 4) cellular toxicity against the anti-viral gene. Hence,
long-term anti-HIV gene therapy solicits the use of conditional vectors
that express anti-HIV genes post-wild type (WT) virus infection. Such
vectors dependent on HIV Rev and Tat have been described by others
(Dinget al., 2002;Unwalla et al., 2004a). This strategy ismost likely tobe
successful by targeting HIV at late steps in the life cycle like assembly
and budding. Hence in this studywe sought to study the potential of DN
HIV Env and Gag mutants that could target the HIV assembly and
budding process and limit the infectivity of progeny virions.
The structural proteins of HIV-1, including the Gag and Env
polyproteins, are essential for completion of the virus life cycle (Freed,
96 A. Joshi et al. / Virology 415 (2011) 95–1061998; Swanstrom and Wills, 1997). HIV-1 Gag is the most abundant
viral protein essential for virion morphogenesis. Expression of the Gag
polyprotein alone is sufﬁcient for the formation of virus like particles
(VLPs) (Freed, 1998; SwanstromandWills, 1997). The Envglycoprotein,
on the other hand, is important for virus entry into target cells. Hence,
targeting the HIV assembly and entry pathways with DN Gag and
Env mutants is likely to limit virus spread long-term by imposing
severe constraints on the emergence of viral mutants. Currently there
are no thoroughly characterized inhibitors of HIV assembly and entry
pathways that show promise for anti-HIV gene therapy.
HIV-1 Gag is comprised of distinct structural and functional
domains that play multiple essential roles in the virus life cycle. The
N-terminal matrix (MA) domain is required for Gag membrane
binding, while the capsid (CA) and nucleocapsid (NC) domains are
important for Gag–Gag interactions and multimerization (Freed,
1998; Joshi et al., 2006; Swanstrom and Wills, 1997). It is known
that certain mutations in the MA and CA domain of HIV Gag are not
only non-functional per se, but also act in a DN fashion by inhibiting
WT virus (Checkley et al., 2010; Kawada et al., 2008; Lee et al., 2009;
Mammano et al., 1994; Muller et al., 2009; Shimano et al., 1999a,b;
Trono et al., 1989). Moreover, since the retroviral Gag proteins are
highly conserved and multimeric, their DN mutants are likely to
exhibit a broad spectrum of inhibition, and hence may be suitable for
gene therapy. Mutations in speciﬁc residues of HIV-1 Env are also
known to interfere with viral integrity (Buchschacher et al., 1992;
Inubushi et al., 1998; Iwatani et al., 2001). However, their mechanism
of interference and the feasibility of their use in combination with Gag
mutants for HIV gene therapy remain undetermined.
To identify themost potent DN inhibitor(s) targeting HIV assembly
and entry, we undertook a thorough in vitro characterization of the
mechanism of action of DN proteins consisting of a panel of Gag and
Env mutants. In the gag gene we used the MA mutant 1GA (Freed
et al., 1994; Kawada et al., 2008) and CA mutants Q155N and Y164A
because of their ability to retain interaction with WT Gag but not be
rescued to produce virions (Mammano et al., 1994), while for the env
gene we selected the cleavage-defective (R515A) or fusion-defective
Env mutant V513E (also known as the 41.2 mutant) (Freed et al.,
1992, 1990; Iwatani et al., 2001) and a combination thereof. Our data
demonstrate that DN mutations in the CA are more potent at
inhibiting WT virus than the DN MA mutant 1GA. Combination of
Gag and Env mutants Y164A/R515A was the most potent at
suppressing WT HIV. Elucidation of the mechanism of inhibition
demonstrated that Y164A/R515A acted at multiple steps of the virus
life cycle, including assembly and release as well as entry and post-
entry of the progeny virions. Interestingly, the inhibition mediated by
R515A was partially attributed to the Env cytoplasmic tail. Thus,
disrupting HIV's structural proteins can be harnessed for development
of potential anti-HIV gene therapy vectors. Furthermore, our approach
of targeting multiple HIV structural genes at the same time is likely to
enhance potency and limit resistance development.
Results
DN HIV-1 Gag and Env mutants are potent inhibitors of WT HIV-1
The aim of this studywas to determine whether targeting the virus
assembly and entry pathway holds potential for anti-HIV gene
therapy. To this end, we chose the MA mutant 1GA, known to be
defective in Gag plasma membrane binding (Freed et al., 1994), and
Q155N and Y164A mutations in the major homology region (MHR) of
the HIV CA (Mammano et al., 1994) as potential candidates for DN
HIV-1 inhibition. With respect to the Env glycoprotein, we selected
the cleavage-defective mutant R515A (Iwatani et al., 2001) and the
fusion-defective mutant V513E (the 41.2 mutant) (Freed et al., 1992,
1990). All the mutant genes were generated in the pNL4-3 full length
HIV as described in Materials and methods. We ﬁrst determinedwhether these mutants were capable of inhibiting WT HIV and the
relative potency of each mutant. To determine the effect of DN
proteins on infectious virus production the virus supernatants derived
from HeLa cells transfected with various ratios of WT and DNmutants
were used to infect TZM cells. TZM is a reporter cell line that expresses
luciferase after infection with HIV and is ideally suited for detection of
infectious HIV. The amount of infectious virus was determined by
gene reporter readout in TZM cells 24 h post-infection. As shown in
Fig. 1A, all of the Gag mutants were capable of inhibiting WT virus,
with pNL4-3/Y164A being the most potent and pNL4-3/1GA being the
least. Among the Env mutants, both Lai/V513E and Lai/R515A
effectively inhibited WT, with the former being a slightly better
inhibitor (Fig. 1B). With respect to the Env mutants, we also
investigated the potential of each mutant to inhibit cell-to-cell fusion.
Env glycoprotein expressed on the surface of infected cells has the
potential to mediate fusion with neighboring cells to form syncytia
which can be determined by cell-to-cell fusion assay in TZM cells
(Garg et al., 2007). Interestingly, the Env/V513E mutant was more
potent than Env/R515A in inhibiting WT Env-mediated cell-to-cell
fusion (Fig. 1C).
While the preceding data demonstrate that the selectedGag and Env
mutants independently are potent DN inhibitors of virus replication we
wanted to know whether a combination of Gag and Env DN inhibitors
would enhance the overall potency. For this purpose we chose the
R515A mutation with the uncleaved Env as a potential therapeutic
candidate for combinationwithvariousGagmutants because, unlike the
V513Emutant, R515A is not processed into gp120 and gp41 subunits of
the Env glycoprotein and hence is not likely to induce toxic side effects
due to release of soluble gp120 (Gougeon, 2003; Perfettini et al., 2005).
Interestingly, a combination of Gag and Env mutations only increased
the potency of inhibition for 1GA Gag (IC50 value lowered from ~24 to
~6, Fig. 1D and Table 1) but not Q155N or Y164A Gag (Fig. 1E and F and
Table 1). This is most likely due to the saturating anti-HIV activity of the
Gag mutants Y164A and Q155N by themselves in our cotransfection
assays. Although these data suggest that DNmutations in HIV Gag alone
are sufﬁcient to strongly inhibit WT HIV, combining these with DN Env
mutants has the advantage of targeting the virus at multiple steps to
limit virus resistance.
The Gag MA and CA mutants inhibit release of WT HIV-1
We next determined the mechanism of inhibition of the DN Gag
mutants. As Gag expression alone is sufﬁcient for virus assembly and
budding we wanted to know the effect of the DN mutants on virus
release from cells. For this purpose we conducted virus release assays
with themutants alone or cotransfected with a 1:1 ratio withWTHIV-
1 DNA. As shown in Fig. 2A, the MA mutant 1GA and the CA mutants
Q155N and Y164A (consistent with Mammano et al., 1994) were
severely defective in virus release by themselves. More importantly,
when transfected at 1:1 ratio the DN mutants inhibited the release of
WT HIV as well. This phenomenon was more pronounced for the
Y164A mutant compared to the 1GA and Q155N mutants (Fig. 2B),
consistent with the infectious virus production seen previously. Thus,
these data suggest that the DN Gag mutants disrupt WT HIV by
inhibiting release of virus particles from the cells.
The Env mutant R515A affects gp160 processing, cell-to-cell fusion and
apoptosis mediated by WT HIV Env
TheEnvglycoprotein ofHIVmediates virus entryby fusionof cellular
and viral membranes. Additionally the role of Env glycoprotein in HIV
pathogenesis is also an important factor to consider if it is to be a target
for anti-HIV gene therapy. Hence we asked what effect DN Env has on
the many functions of the Env glycoprotein. First we looked at the
mechanism of R515A mediated inhibition of WT virus infectivity by
examiningwhether it interfered with gp160 processing. As anticipated,
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Fig. 1. DN Gag and Env mutants severely inhibit WT HIV. (A and B) HeLa cells were either transfected with WT HIV proviral DNA alone, DN Gag or Env HIV mutant DNA alone or
varying ratios of WT HIV along with DN mutants. The total DNA amount for transfection was kept constant by using carrier pUC 18 DNA. Virus supernatants were harvested 48 h
post-transfection and centrifuged, and an equal volume of virus input was used to infect indicator TZM cells. TZM cells were lysed 24 h post-infection and read on a luciferase plate
reader. Readings were normalized and graphs ﬁtted using the SigmaPlot software. Data are mean±SE from 3 independent experiments. (C) HeLa cells were transfected with Env
expression constructs for the V513E or R515A mutant along with WT HIV Env at various ratios. The total DNA amount for transfection was kept constant by using carrier pCDNA3.1
DNA. Twenty-four hours post-transfection, an equal number of TZM cells were added to each well. Cells were cocultured for 6–7 h followed by analysis on a luciferase plate reader.
Readings were normalized and graphs ﬁtted using the SigmaPlot software. Data are mean±SE from 2 independent experiments with triplicate wells in each experiment. (D–F) HeLa
cells were transfected with varying ratios of the double Gag and Env DN mutant DNA along with WT HIV-1 and assayed as in part A and B above.
97A. Joshi et al. / Virology 415 (2011) 95–106the R515A mutation has no effect on release of WT virus from cells
(Fig. 3A). However, the R515A mutant displayed severely defective
gp160 processing, as levels of gp120weremarkedly reduced in both cell
and viral lysates (Fig. 3A). Interestingly, the levels of virion-associated
gp120 were also substantially reduced in cotransfections consisting of
WT+R515A DNA (Fig. 3A), suggesting a DN effect.
HIV Env-mediated fusion has been implicated in bystander
apoptosis and T cell death during HIV-1 infection (Garg and
Blumenthal, 2008; Garg et al., 2007) which is related to the fusogenic
activity of the protein. Hence, we wanted to determine the fusion and
apoptotic potential of the DN Env mutants themselves and the effect
they have on WT Env-mediated apoptosis and fusion. As shown in
Fig. 3B, both V513E and R515A Env mutants were severely defective
in cell-to-cell fusion and consequently apoptosis induction whencompared to WT Env. Moreover, a 1:1 ratio of DN Env mutants with
WT Env reduced both cell-to-cell fusion and apoptosis (Fig. 3B),
suggesting that the use of the Env mutants for HIV gene therapy will
have the added beneﬁt of modestly limiting bystander apoptosis.
Taken together, these ﬁndings suggest that the Env mutant R515A is
multifunctional by affectingWT Env processing, cell-to-cell fusion and
bystander apoptosis in addition to inhibiting virus infection.
The MA and CA mutants affect WT Gag plasma membrane localization
and virion morphology
We further characterized the DN mutants with respect to defects
in plasma membrane (PM) localization and virion morphology using
ﬂuorescence and electronmicroscopy. By cotransfection of various DN
Table 1
IC50 values for various DN mutants used in the study
DN mutant IC50±SE
1GA 24±4.9
1GA+R515A 6.4±4
Q155N 8.3±3.1
Q155N+R515A 7.4±4.6
Y164A 5.4±1.5
Y164A+R515A 4.6±.79
R515A 16.3±2.0
V513E 14.7±.70
Inhibitory IC50 concentrations for the single Gag and Env
mutants or the double DN Gag+Env mutants were
determined using the SigmaPlot software. IC50 concentration
represents percent ofmutantDNA required for 50% inhibition of
WT HIV.
98 A. Joshi et al. / Virology 415 (2011) 95–106mutants with WT Gag RFP, we were able to determine defects in PM
localization of the WT Gag induced by the various DN mutants. As
shown in Fig. S1, the 1GA Gag mutant was severely defective in PM
localization as evident by diffuse cytosolic Gag staining as opposed to
punctuate PM Gag staining pattern for WT Gag, while the CA mutants
Q155N and Y164A showed lower, yet signiﬁcant defects in membrane
recruitment. This defect was also seen when DN mutants were
cotransfected at a 1:1 ratio with WT Gag-mRFP and analyzed by
ﬂuorescence microscopy. As shown in Fig. 4A, the 1GA mutant mostFig. 2.DN Gagmutants are severely defective in virus release and inhibitWT HIV-1 release. H
HIV along with the DN HIV Gag mutants. The total DNA amount for transfection was kept c
labeled with [35S]Met/Cys, and cell and virus lysates were immunoprecipitated with HIV
calculated as the ratio of virion-associated Gag to total cell+virion-associated Gag. Data arsigniﬁcantly affected membrane localization of WT Gag (diffuse
staining) followed by Y164A and Q155N. On the other hand, as
expected, the R515A Env mutant showed punctuate PM Gag staining
pattern, suggesting that it had no effect on WT Gag membrane
localization. We next determined by electronmicroscopywhether the
DN mutants induced defects in virion morphology. The DN Gag
mutants induced severe defects in WT HIV-1 virion morphology as
evident by eccentric cores and immature as well as aberrantly shaped
virions (Fig. 4B and C). The defects in virusmembrane localization and
budding as well as virion morphology demonstrate that the DN Gag
mutants disrupt multiple late steps in the virus replication pathway.
Replication potential of DN mutants
We next sought to examine whether the DN mutants described
above were capable of undergoing multiple-round replication in T cell
lines like Jurkat and MT4 cells. It is essential to rule out this possibility
as a gene therapy vector should not be able to replicate either by itself
or upon recombination with WT virus. As shown in Fig. S2, both in
Jurkat and MT-4 T cells, WT pNL4-3 and WT Lai replicated to high
levels between days 6 and 10. However, none of the other Gag or Env
mutants were replication competent even in the highly permissive
cell line MT-4, suggesting that they were severely defective. We next
tested whether virus particles produced after co-transfection of WT
and DNmutants were capable of multiple rounds of infection. For this
purpose, we infected Jurkat T cells with equal RT cpm of virus derivedeLa cells were transfected with (A) HIV DN Gagmutants alone or (B) with a 1:1 ratioWT
onstant by using carrier pUC 18 DNA. Twenty-four hours post-transfection, cells were
-Ig followed by resolution on an SDS–PAGE gel and ﬂuorography. Virus release was
e mean±SD from 2 independent experiments.
Fig. 3. The HIV Env mutant R515A affects gp160 processing, cell-to-cell fusion and apoptosis. (A) HeLa cells were transfected with WT HIV alone, HIV-R515A mutant alone or a 1:1
ratio of WT HIV and HIV-R515A mutant. Twenty-four hours post-transfection, cells were labeled with [35S]Cys and processed as described in Fig. 2. Data are mean±SD from 2
independent experiments. (B) HeLa cells were transfected withWT HIV Env construct or the various Envmutants. Twenty-four hours post-transfection, an equal number of TZM (for
fusion) or SupT1 (for apoptosis) T cells were added to the wells. Fusion was assayed 5–6 h post-TZM addition using the britelite plus reagent. Apoptosis was measured after
overnight coculture of SupT1 cells using annexin V staining. Data are mean±SD of triplicates. One representative of 2 independent experiments is shown.
99A. Joshi et al. / Virology 415 (2011) 95–106from HeLa cells transfected with different ratios of WT and Y164A/
R515A mutant. As shown in Fig. 5A, the 1:8, 1:16 and 1:32 Y164A/
R515A:WT derived virus replicated with WT kinetics or better. This
could be due to the fact that incorporation of R515A inhibits bystander
apoptosis, thereby making more cells available for virus replication
consistent with previous ﬁndings of Garg et al (2007). However 1:4-
derived virus replicated with delayed kinetics, peaking at day 30 post-
infection, and 1:1 derived virus did not show any replication up to day
50 post-infection. These data suggest that the combination of DN Gag
and Env mutants is capable of severely restricting the replication of
WT HIV in T cell lines.
The DN Gag and Env mutants affect WT HIV at the entry/post-entry step
The defects in virion morphology induced by the DN Gag mutants
seen above suggested that the progeny virions produced may also be
infection defective. Furthermore the step at which the Env DN
mutants inhibit virus infection also needs to be studied. For this
purpose we conducted studies to determine whether the DN effect of
Gag and Envmutantswasmediated at the entry or post-entry level. To
determine if the single and double HIV Gag and Env mutants are
themselves defective at the entry step, TZM cells were infected with
equal RT cpm (to account for the defective release of the Gagmutants)
of the indicated viruses. As shown in Fig. S3, all the DN Gag mutants
but not Env mutant R515A were defective in virion release (as
determined by released RT activity) but all the Gag and Env mutants
were defective in virus infectivity (luciferase activity, Fig. 5B). To
determine if the defect in infectivity was only at the entry level or also
at some post-entry step, TZM cells were infected with equal RT cpm of
the indicated viruses complemented with VSV-G. Interestingly, all ofthe mutants were defective even when complemented with VSV-G,
suggesting a defect at a post-entry stage, although we cannot exclude
the possibility that the DN mutants may also have an effect on VSV-
G-mediated entry. We then determined whether the DN mutants
inhibited WT virus at an entry or post-entry step. To this end, we
transfected HeLa cells with a 1:1 ratio of HIV-WT and indicated HIV
DN DNAs and collected the virus in the supernatants. Subsequently,
TZM cells were infected with normalized RT cpm of the virus stocks
derived from HeLa cells and infectivity was determined by luciferase
activity. As shown in Fig. 5C, in the presence of the DN mutants, the
WT virus was defective both in entry (−VSV-G) and potentially at
post-entry stages (+VSV-G). These data indicate a potential for both
the DN Gag and Envmutants to inhibitWT HIV at multiple steps in the
virus life cycle.
The Env R515A mutant is severely defective in early stages of reverse
transcription
As shown in Fig. 5, the VSV-G-mediated viral infectivity data
suggested that the Gag and Env mutants may have defects at a post-
entry step. To determine whether they harbor defects in reverse
transcription, we conducted real-time PCR from cells infected with
equal input RT cpm of various Gag and Env mutant viruses or a 1:1
ratio of WT and mutant viruses to determine if the DN mutants
affected reverse transcription of WT virus. Real-time PCR for early
reverse transcription products using env gene primers (Lee et al.,
2009) showed that the R515A mutant was severely defective in
initiation (Fig. 5D) of reverse transcription and inhibited WT virus
reverse transcription process. A similar defect was also seen with the
Y164A Gag mutant but to a lesser extent. The 1GA and the Q155N
100 A. Joshi et al. / Virology 415 (2011) 95–106mutants also showed varying degrees of defects for early reverse
transcription products but to a lesser extent. These data corroborate
the ﬁndings fromVSV-G rescue experiments suggesting a defect in the
DN Gag and Env mutants at a post-entry step as well.
The cytoplasmic tail partially contributes to the inhibitory effect of
R515A Env
The fact that VSV-G complementation assays failed to rescue
R515A virus suggests defects in a post-entry step, raising questions
regarding the mechanism by which the R515A Env affects virus
uncoating. It has been shown that the viral Gag and Env remainFig. 4. DN Gag mutants are defective in Gag membrane binding. (A) HeLa cells were transfec
Cells were ﬁxed 24 h post-transfection and analyzed by ﬂuorescence microscopy. Graph re
were transfected with DN HIV Gag or Env mutant proviral DNA alone or a 1:1 combination o
electron microscopy. (C) Graph represents number of virus particles with normal, immatur
were observed in cells transfected with 1GA, Q155N or Y164A Gag mutants alone. Scale=1associated in a mature virion via residues in the MA in Gag and the
gp41 cytoplasmic tail. Dissociation of Env from Gag is important for
proper virion infectivity (Freed and Martin, 1995a,b, 1996; Murakami
and Freed, 2000a,b; Wyma et al., 2000). Since the R515A Env could
only be minimally rescued with VSV-G, we speculated that defects in
Gag/Env dissociation post-fusion may be responsible for the apparent
post-entry defects. To test this, we constructed a tail-deleted version
of HIV R515A (CTDel/R515A) and looked at its infectivity in TZM cells
in the presence or absence of VSV-G. It needs mention here that HIV-
CTDel mutant by itself shows signiﬁcantly reduced Env incorporation
and hence lower infectivity when compared toWTHIV-1. As shown in
Fig. 6A, while HIV R515A and CTDel/R515A were severely impaired inted with 1:1 ratio of DN HIV Gag or Env mutant proviral DNA along with HIV Gag-mRFP.
presents number of cells showing diffuse pattern of Gag RFP expression. (B) HeLa cells
f WT and indicated DNmutants. Cells were ﬁxed 24 h post-transfection and analyzed by
e or aberrant morphology from 15–20 images for each mutant. Note: No virus particles
00 nm.
Fig. 4 (continued).
101A. Joshi et al. / Virology 415 (2011) 95–106infectivity assays in TZM cells, the infectivity of CTDel/R515A but not
R515A alone could be rescued partially when complemented with
VSV-G. Having seen that the CTDel/R515A is partially restored in
infectivity, we looked at its DN inhibitory potential in virus cell fusion
assays. As shown in Fig. 6B, the dominant negative effect of HIV-
CTDel/R515A was signiﬁcantly less than R515A in virus cell fusion
assays. These data suggest that the DN inhibitory effect of R515A Env
is partially dependent on the cytoplasmic tail.
The lentivirus Y164A/R515A inhibits HIV replication in MDMs derived
from transduced stem cells
The long-term objective of our study is to develop anti-HIV vectors
that can be used to transduce CD34+ hematopoietic stem cells for
reconstitution in AIDS patients. Before conducting in vivo studies, ex
vivo testing of the vectors can be conducted in cord blood derived
CD34+ cells differentiated into macrophages and challenged with
HIV. For these ex vivo studies we cloned the Gag-Y164A and Env-
R515A mutant into a lentivirus vector (Fig. S4). As shown in Fig. 7A,
expression from the lentivirus expressing Gag-Y164A alone was
signiﬁcantly reduced compared to the lentivirus expressing Gag and
Env Y164A/R515A together presumably due to lack of Rev protein and
Rev responsive element (RRE) that functions in regulating the
transport of the full-length and partially spliced HIV RNAs out of
the nucleus (Felber et al., 1989; Hadzopoulou-Cladaras et al., 1989).
CD34+ stem cells isolated from human cord blood (purity of 94%,
Fig. 7B) were expanded in vitro and subsequently transduced with
either a lentiviral vector expressing GFP (TyEFeGFP) or the Y164A/
R515A DNmutant. The transduction efﬁciency was ~19% and ~16% for
the TyEFeGFP versus Y164A/R515A mutant, respectively, as assessed
by GFP and HIV p24 expression (Fig. 7C). The transduced stem cells
were then differentiated into MDMs using human-M-CSF. In a
separate experiment, stem cells were ﬁrst differentiated into MDMs
using M-CSF prior to transduction with the above-mentioned
lentiviral vectors (transduction efﬁciency ~20%). Following MDMdifferentiation, cells were infected with HIV NL-AD8 and monitored
for virus replication over a period of time. As shown in Fig. 7, MDMs
derived from transduced stem cells (Fig. 7D and Fig. S5C) or directly
transduced (Fig. 7E and Fig. S5D) showed signiﬁcantly reduced virus
replication over timewith the lentivirus vector expressing the Y164A/
R515A mutant when compared to cells transduced with TyEFeGFP
vector in 2 independent experiments. At the end of the experiment,
stem cells transduced with TyEFeGFP vector in 7D were ﬁxed and
analyzed for GFP expression by microscopy. As shown in Fig. 7F, GFP
expression was evident in approximately 20–40% of MDMs, suggesting
that gene expression was maintained over a prolonged period of time.
Moreover, transduction with the lentiviral vectors led to normal
differentiation of stem cells into MDMs following M-CSF treatment
(Fig. S5AandB). These data suggest that theDNGag andEnv-expressing
lentiviral vector described in this study can induce stable stem cell
transduction andholds promise asa gene therapy tool forHIV inhibition.
Discussion
Gene therapy for HIV has gradually become a realistic possibility
with the advances in CD34 stem cell transduction and repopulation in
humans (Deeks and McCune, 2010; Holt et al., 2010; Kohn, 1999;
Kohn and Sarver, 1996; Rossi et al., 2007b; Urnov et al., 2010;Weaver,
2010). The recent ﬁndings by Hutter et al. (2009), in which CCR5Δ32
homozygous stem cells were transplanted into an HIV patient
resulting in undetectable virus replication for 20 months even in the
absence of antiretroviral therapy, strengthen the notion that stem
cell-mediated gene therapy holds potential. These advances have
paved the way for establishing much needed novel and potent anti-
HIV gene therapy approaches, especially for patients failing the
currently available drug regimens. In this respect, DN Gag and Env
proteins, either alone or in combination, represent an unexploited
novel approach for anti-HIV gene therapy.
The use of DN Gag and Env mutants to inhibit WT HIV is unique as
currently there are few chemotherapeutic drugs or other forms of
Fig. 5. HIV DN Gag and Env mutants restrict replication of WT virus. (A) Jurkat T cells were infected with equal RT cpm (20,000) of virus derived from HeLa cells transfected with
different ratios of WT and Y164A/R515A mutant. Culture supernatants were harvested every 3 days for determination of RT activity. One representative from 3 independent
experiments is shown. The 1:4 ratio derived virus always replicated with a delay although the virus peak varied between experiments. (B and C) The DN Gag and Env mutants affect
WT HIV at the entry/post-entry step. HeLa cells were transfected with indicated DN Gag and Env single or double mutant plasmid DNA alone (B) or with the indicated DN Gag and
Env single or double mutants along with WT HIV plasmid at a 1:1 ratio (C) in the presence (+) or absence (−) of VSV envelope expression plasmid. Culture supernatants were
harvested 48 h post-transfection, assayed for RT activity and used to infect TZM cells with 20,000 RT cpm of the indicated virus stocks. Plates were read for luciferase activity 24 h
post-infection. Data represent mean±SD from triplicate observations. One representative from 2 independent experiments is shown. (D) The Gag Y164A and Env R515A DN
mutants exhibit defects in early stages of reverse transcription. Jurkat T cells were infected with equal RT cpm (20,000) of virus stocks derived from HeLa cells transfected with DN
Gag and Env single mutants alone or with the mutants transfected with a 1:1 ratio with WT HIV-1. DNA was isolated 24 h post-infection and quantitated, and an equal DNA amount
was used for real-time PCR using primers speciﬁc for the Env gene. The copy number was calculated based on HIV-1 plasmid DNA standard with known copy number. Equal input
DNA amount was veriﬁed by PCR for the CCR5 gene. One representative of 2 independent experiments is shown.
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2010). Another aspect of these structural proteins is that the DN effect
is via protein–protein interaction rather than protein–RNA interaction
as in the case of DN Rev and Tat. This suggests that resistance against
thesemutantswould be less likely. Another attraction of using DNGag
mutants for anti-HIV therapy, especially those derived from the CA, is
that amongst the various DNmutants of Gag, Pol, Env, Tat and Rev, theGag CA mutants are the most potent at inhibiting WT virus (Shimano
et al., 1999a). A combination of Gag and Env would not only increase
the potency but make it difﬁcult for the virus to attain breakthrough
resistance.
We characterized several Gag and Envmutants for DN inhibition of
HIV replication. Mammano et al. (1994) described the Q155N and
Y164A CA mutations and their DN effect while studying the role of
Fig. 6. The cytoplasmic tail partially contributes to the inhibitory effect of R515A Env. (A) HeLa cells were transfected with the indicated Env mutant DNA in the presence (+) or
absence (−) of VSV envelope. Virus supernatants were collected 48 h post-transfection and used to infect TZM cells. Data from TZM cells was analyzed 24 h post-infection by reading
the plate on a luciferase reader. Data represent mean±SD from triplicate observations. One representative from 2 independent experiments is shown. (B) HeLa cells were
transfected with varying ratios of pNL4-3 CTDel plasmid alongwith CTDel/R515A. Virus supernatants were used to infect TZM cells and assayed as in (A). Curves were ﬁtted using the
SigmaPlot software. Data are mean±SD from triplicate observations. One representative from 2 independent experiments is depicted.
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mutations could be used for anti-HIV gene therapy and the
mechanism by which they show DN effects remained undetermined.
Also, it is unclearwhether Gag and Envmutants in combinationwould
show better inhibition or other potential beneﬁts when compared to
single mutants. Our data show that CA mutants are more potent
inhibitors of WT virus thanMAmutants as evident from the enhanced
inhibitory activity of Q155N and Y164A over 1GA. Characterization of
the mechanism of action of the Gag mutants revealed some
interesting ﬁndings. For one, the Y164A mutant is not only restricted
in budding by itself but also inhibits release ofWTHIV Gag, suggesting
a DN effect at this step. Moreover, ﬂuorescence microscopy analysis of
DN Gag mutants alone or of WT Gag in the presence of 1:1 ratio of DN
Gag mutants suggested defects in Gag membrane localization.
However, when equal RT cpm of virus derived from co-transfection
assays was used for second-round infections, the progeny virus
particles were once again severely defective in infectivity. These data
suggest that Y164A inhibits not only release but also infectivity of WT
virions. The defects induced by the DN Gag when used to inhibit WT
Gag were evident from our electron microscopy analysis where we
saw aberrant virion morphology at a 1:1 ratio of WT to DN DNA. That
these virions were defective in a post-entry event was further
suggested by the VSV-G rescue experiments, in which WT+Y164A
virions could not be rescued for infection even after pseudotyping
with VSV-G. Finally, real-time PCR analysis using primers to detect
early stages of reverse transcription conﬁrmed these ﬁndings. This
suggests that these aberrant virions most likely are defective at both
entry and post-entry steps.
The Env mutants that have been studied for HIV inhibition include
R515A and V513E (41.2). R515A is defective in the cleavage site
between gp120 and gp41 and hence produces an uncleaved gp160
precursor protein which is obviously defective in fusion (Iwatani et al.,
2001). V513E on the other hand has a substitution in the gp41 fusion
peptide resulting in loss of fusion activity (Freed et al., 1992). While
the mechanism by which these proteins are defective is different,
interestingly they both act as DN inhibitors of WT HIV. We chose to
study R515A in greater detail because of the lack of processing of gp160
to gp120 and gp41 would minimize soluble gp120 shedding from
transduced/infected cells and limit any toxic side effects mediated by
circulating gp120 (Gougeon, 2003; Perfettini et al., 2005). Interestingly,
we also found that R515A was not only defective by itself but also
inhibitedWT virion infection at 1:1 ratio, indicating a DN phenomenon.
Characterization of this DN effect using VSV-G rescue experimentssuggested that the inhibition was not restricted to viral entry but
also potentially at a post-entry step as VSV-G failed to rescue virion
infectivity toWT levels. These data however need to be interpretedwith
caution as it is not known whether the DN Env mutants have a
deleterious effect on VSV-G incorporation or entry. Based on the VSV-G
rescue experiments we hypothesized that the post-entry defects seen
with R515A might be mediated by interaction of the tail of uncleaved
Env with Gag as the interaction of the HIV gp41 cytoplasmic tail with
Gag has been implicated in post-entry defects in certain Gag and Env
mutants (Freed andMartin, 1995a,b, 1996;Murakami and Freed, 2000a,
b; Wyma et al., 2000). This was supported by our observation that
deletion of the gp41 cytoplasmic tail in context of theHIVR515Amutant
(CTDel/R515A) resulted in a better recovery of virus infectivity with
VSV-G pseudotyping as well as reduced dominant negative effects.
The ultimate goal of anti-HIV gene therapy is to be able to
transduce CD34+ stem cells ex vivo and then repopulate in HIV-
infected patients to regenerate an HIV- resistant immune system. To
this end, we tested our vectors for transduction of CD34+ stem cells
ex vivo followed by differentiation into macrophages and challenge
with HIV. Although our transduction efﬁciencies were low (20–40%
in 2 different experiments), the fact that there was inhibition of
HIV replication in stem cell-derived MDMs even under limited
transduction efﬁciency is quite encouraging. Although it is possible
that p24 staining underestimates the percentage of transduced cells
the proof of principle of the potency of this dual Gag and Env lentiviral
construct is demonstrated here. We believe that sorting of lentiviral
transduced cells for analyses will further enhance the potency of
inhibition. It is tempting to speculate further that the transduced cells
could interfere with cell–cell transmission and/or cell–cell fusion
between untransduced cells, thereby limiting HIV replication. Studies
are under way to test this hypothesis as it would provide an added
beneﬁt if/when these vectors are used for gene therapy purpose.
Although our results suggest that transduced cells maintain long-
term gene expression, the expression of DN forms of HIV proteins in
differentiated T cells may be detrimental due to cellular toxicity or
immune recognition and CTL mediated lysis. Recently a number of
groups have proposed and developed conditional vectors that express
the DN HIV gene only after infection with WT HIV. This has been
achieved by making the DN gene ORF dependent on HIV rev and tat
proteins (Ding et al., 2002; Unwalla et al., 2004a). This strategy would
produce the DN inhibitor of HIV only in the cells that get infected. This
suggests that the DN inhibitors should be able to inhibit late steps in
HIV life cycle like assembly and budding and subsequent infectivity
Fig. 7. The lentiviral vector expressing Y164A/R515A DN mutants inhibits HIV replication in hematopoietic stem cell-derived MDMs. (A) HeLa cells were transfected with WT HIV-1
or the lentiviral vector expressing Gag-Y164A, Gag Y164A and Env R515A or empty lentiviral vector. Cells were labeled with [35S]Met/Cys and analyzed as described in Fig. 3.
(B) CD34+ cells were isolated from human cord blood and the purity of the isolated population was determined by staining with human CD45 and CD34 antibodies. (C) CD34+ stem
cells were transduced with GFP expressing lentiviral vector TyEFeGFP or Y164A/R515A lentiviral vector. Cells were assayed for GFP or p24 expression 72 h post-transduction by ﬂow
cytometry. (D) Stem cells transduced with the above lentiviral vectors were treated with GM-CSF for 7–10 days for differentiation into MDMs. Cells were then infected with pNLAD8
virus. Culture supernatants were harvested every other day for determination of RT activity. (E) Cord blood derived stem cells were expanded for 4 days in the presence of Stem Span
media and CC110 cocktail. The cells were then treated with GM-CSF for 7–10 days for differentiation into MDMs and then transduced with the above lentiviral vectors. Forty-eight
hours post-transduction, cells were infectedwith pNLAD8 virus. Culture supernatants were harvested every other day for determination of RT activity. (F) Stem cells transduced with
TyEGFP lentivirus in (D) were analyzed for GFP expression at day 22.
104 A. Joshi et al. / Virology 415 (2011) 95–106of progeny viruses. We believe that our Gag and Env DN vectors
represent good candidates for adaptation into conditional vectors.
Further studies are under way to delineate the minimal Gag and Env
domains required for DN HIV inhibition for improvement/develop-ment of this vector for in vivo anti-HIV gene therapy. Moreover,
studies are required for validation of this vector for HIV inhibition in
vivo which is now possible with the newer humanized mouse models
for HIV.
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Cells, transfection, infection and reagents
HeLa and 293T cells were maintained in DMEM supplemented
with 5% or 10% fetal bovine serum (FBS), respectively. Transfection of
HeLa and 293T cells was performed using the ExGen 500 reagent
(Fermentas). All virus stocks were prepared in HeLa cells unless
otherwise indicated. pNL(AD8) virus stocks for infection of monocyte
derived macrophages (MDMs) were prepared in 293T cells. TZM-bl
cells were obtained from J. Kappes through the NIH AIDS Research and
Reference Reagent Program and cultured in DMEM supplementedwith
10% FBS. TZM-bl infections were performed in the presence of 20 μg/ml
DEAE dextran (Sigma). HIV immunoglobulin (HIV-Ig) was provided by
the NIH AIDS Research and Reference Reagent Program. SupT1 and
Jurkat T cellsweremaintained in RPMImediumsupplementedwith 10%
FBS. Human cord blood was obtained from NDRI (Philadelphia, PA)
and stemcellswere isolated using the Easy SephumanCD34+selection
kit (Stem Cell Technologies). CD34+ cells were cultured in Stem
Span SFEM media supplemented with the CC110 cocktail (Stem Cell
Technologies). Differentiation of CD34+ cells into macrophages was
induced by recombinant humanM-CSF (100 ng/ml) fromR&D Systems,
Minneapolis, MN.
Virus replication, virus cell fusion, cell-to-cell fusion and PCR assays
For virus replication, Jurkat T cells were infectedwith 20,000 RT cpm
of different virus stocks. Culture supernatants were harvested and cells
were split every other day or every 3 days for measurement of RT
activity. Virus cell fusion assays were conducted as described before.
TZM cells were infected with equal volumes or equal RT cpm of virus
stocks in the presence of 20 μg/ml DEAE dextran. Cells were lysed
approximately 24 h post-infection using the britelite plus reagent
(PerkinElmer) andplateswere readona luciferase reader. Curveﬁts and
IC50 calculations were performed using the SigmaPlot software. Cell to
cell fusion/apoptosis assays were conducted as described previously
(Garg et al., 2009). Brieﬂy, HeLa cells were transfected with the various
HIV Env expression constructs. Twenty-four hours post-transfection, an
equal number of TZM (for fusion assays) or 5 times more SupT1 (for
apoptosis detection) cells were added to the wells. Fusion was assayed
5–6 h post-addition of TZM cells using the britelite plus reagent and
reading plates on a luciferase plate reader. Apoptosis was measured
after overnight coculture of SupT1 cells using annexin V (BD Bio-
sciences) staining and analysis using the BD Facs Canto ﬂow cytometer.
For detection of early and late reverse transcription products by real-
time PCR, DNA was isolated using the QIAamp DNA Blood Mini Kit
(Qiagen). Real-time PCR was conducted using the SYBR Green PCR
master mix (Applied Biosystems). Primers for detection of early
envelope based PCR products have been described by Lee et al.(2009).
CCR5 gene was used as the internal control for calculation of delta delta
CT. Results were expressed as fold decrease fromWT infected cells.
DNA constructs
The full length HIV proviral clone pNL4-3 (Adachi et al., 1986), its
myristoylation-deﬁcient mutant pNL4-3/1GA (Freed et al., 1994) and
HIV molecular clone Lai and Lai/CTDel have been described previously
(Garg et al., 2007). The CCR5-tropic clonepNL(AD8)has beenpreviously
described (Freed et al., 1995) . TheHIVGagmutantswere constructed in
pNL4-3 derived Gag using speciﬁc primers and the site directed
mutagenesis kit (Stratagene). The Env mutants were constructed in
the Lai Env backbone as above. Double Gag and Env mutants were
constructed by replacing the EcoR1/Xho1 fragment containing the
respective mutations into the pNL4-3 backbone. Molecular clone
encoding Gag-monomeric red ﬂuorescent protein (mRFP1) (pNL4-3/
Gag-mRFP) has been describedpreviously (Chukkapalli et al., 2008) andwas kindly provided by V. Bokyo and Wei-Shau Hu. For cloning the
Gag-Y164A and Env-R515A mutants into a lentiviral vector, we ﬁrst
ampliﬁed the Y164A Gag region from our NL4-3 based vectors and used
TOPO cloning to insert the Gag region into the ViraPower Lentiviral
expression systems (Invitrogen) to generate pLenti-Y164A. Subse-
quently the Env region fromR515AEnv vectorwas cutwith EcoR1Xho1
and subcloned downstream of the Gag region to generate pLenti-
Y164A/R515A. Lentiviruses were prepared by transfecting 293T cells
with the lentiviral vector and helper constructs in combination with
VSV-G plasmid for pseudotyping as per the manufacturer's protocol
(Invitrogen). GFP expressing control lentiviral vector (pTY-EFeGFP)was
kindly provided by the AIDS reference reagent program and packaged
the same as above.
Radioimmunoprecipitation
One day post-transfection, cells were metabolically labeled with
[35S]Met/Cys (PerkinElmer) in RPMI-1640medium supplementedwith
10% FBS but devoid of Met and Cys. For Env incorporation assays, cells
were labeled with [35S]Cys (PerkinElmer) in RPMI-1640 medium
supplemented with 10% FBS but devoid of Cys. Procedures for
preparation of cell lysates, ultracentrifugation of virions, and immuno-
precipitation of cell and virion-associated material with HIV-Ig have
been described elsewhere (Freed et al., 1994). Virus release efﬁciency
was calculated as the amount of virion p24 divided by total Gag (cell
Pr55Gag+cell p24+virion p24).
Immunoﬂuorescence and EM analysis
Immunostaining of cells was performed as described (Joshi et al.,
2006), with minor modiﬁcations. Cells plated on Nunc chamber slides
were rinsed with phosphate-buffered saline (PBS) and ﬁxed with 3.7%
formaldehyde in 100 mM sodium phosphate buffer (pH 7.2) for
20 min. Following ﬁxation, cells were thoroughly rinsed with PBS,
permeabilized using 0.1% Triton X-100/PBS for 2 min, and incubated
for 10 min with 0.1 M glycine/PBS to quench the remaining aldehyde
residues. Cells were then blocked with 3% BSA/PBS for 30 min,
followed by incubation for 1 h with primary antibody appropriately
diluted in 3% BSA/PBS. After 3 washes in PBS, cells were incubated for
30 min with secondary antibody diluted in 3% BSA/PBS. Cells were
then washed andmounted using Aqua Poly/Mount (Polysciences Inc).
Images were acquired using the NikonTi microscope and analyzed
using the NIS Elements AR software. For EM analysis, transfected cells
were ﬁxed using buffer containing 2% glutaraldehyde and 100 mM
sodium cacodylate and stored at 4 °C. Samples were then sectioned
and analyzed by transmission EM (Freed et al., 1994).
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